Cardiol Therapeutics Inc. (TSX:CRDL)

Cardiol Therapeutics Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	0.08	-
Gross Profit	-	-	-	0.08	-
Selling, General & Admin	26.26	15.56	22.37	27.87	10.09
Research & Development	14.01	14.22	18.96	10.87	10.6
Operating Expenses	40.28	29.79	41.34	38.74	20.69
Operating Income	-40.28	-29.79	-41.34	-38.66	-20.69
Interest & Investment Income	1.19	2.04	1.24	0.11	0.08
Currency Exchange Gain (Loss)	2.14	-0.71	2.76	1.89	-0.03
Other Non Operating Income (Expenses)	0.27	0.33	6.41	5.03	0.01
Pretax Income	-36.68	-28.13	-30.93	-31.64	-20.64
Net Income	-36.68	-28.13	-30.93	-31.64	-20.64
Net Income to Common	-36.68	-28.13	-30.93	-31.64	-20.64
Shares Outstanding (Basic)	72	64	63	43	30
Shares Outstanding (Diluted)	72	64	63	43	30
Shares Change (YoY)	11.02%	3.13%	44.61%	44.77%	15.63%
EPS (Basic)	-0.51	-0.44	-0.49	-0.73	-0.69
EPS (Diluted)	-0.51	-0.44	-0.49	-0.73	-0.69
Free Cash Flow	-25.08	-25.24	-27.3	-23.55	-9.17
Free Cash Flow Per Share	-0.35	-0.39	-0.44	-0.55	-0.31
Gross Margin	-	-	-	100.00%	-
Operating Margin	-	-	-	-49091.93%	-
Profit Margin	-	-	-	-40170.45%	-
Free Cash Flow Margin	-	-	-	-29904.22%	-
EBITDA	-40.11	-29.59	-41.16	-38.44	-20.46
D&A For EBITDA	0.16	0.2	0.18	0.22	0.23
EBIT	-40.28	-29.79	-41.34	-38.66	-20.69

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.